Fig. S1 from The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Supplementary Fig S1. CBL0137 in combination with cisplatin attenuates SCLC tumor growth. H82 SCLC cells, mixed with Matrigel (1:1), were inoculated subcutaneously into the flanks of NSG mice (n=8). Once the tumors reached â^¼50 mm3, the mice were randomized to treatment with vehicle control, CBL0137 (CBL) alone (60 mg/kg i.v., weekly), cisplatin (Cis) alone (5 mg/kg i.p., weekly), or CBL0137 plus cisplatin (CBL+Cis). Tumor diameters were measured 3 times a week for 32 days. The results are represented as means {plus minus} SE.